ASMB Assembly Biosciences

Assembly Biosciences Announces October Conference Participation

Assembly Biosciences Announces October Conference Participation
EN
05/10/2020

Underlying

ASMBAssembly Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assembly Biosciences

 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Reports Third Quarter 2025 Financial Results and ...

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates – Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of weekly ora...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generati...

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® – Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for its next-generation investigational capsid assem...

November 7, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Announces Upcoming Investor Conference Participat...

Assembly Biosciences Announces Upcoming Investor Conference Participation SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor conferences. H.C. Wainwright Liver Disease Virtual ConferenceAnuj Gaggar, MD, PhD, chief medical officer, will present in a pre-recorded fireside chat that will be available on demand during the H.C. Wainwright Liver Disease Vir...

October 14, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-P...

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe – Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes –  – Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo – – Interim data evaluating a m...

October 10, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Announces Pricing of $175 Million in Equity Finan...

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of ...

August 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch